Vaxart (OTCMKTS:VXRT) Posts Earnings Results, Misses Expectations By $0.04 EPS

Vaxart (OTCMKTS:VXRT) posted its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.04), Zacks reports. Vaxart had a net margin of 15.88% and a return on equity of 53.04%.

Vaxart Price Performance

Shares of VXRT traded down $0.03 during midday trading on Thursday, reaching $0.37. 434,774 shares of the stock were exchanged, compared to its average volume of 288,712. The company has a market capitalization of $90.17 million, a price-to-earnings ratio of 2.31 and a beta of 1.15. Vaxart has a twelve month low of $0.33 and a twelve month high of $0.84. The business’s 50-day moving average price is $0.46 and its 200 day moving average price is $0.58.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Hold rating. According to MarketBeat, Vaxart currently has a consensus rating of “Hold”.

Vaxart Company Profile

Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.